Refine your search

Search Results within category "Dentistry and Oral Health"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
1 Study Matches

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

Participants with symptomatic Oral Lichen Planus lesions will be treated with Rivelin® patches containing either 0, 1, 5, or 20 μg clobetasol per patch. Each participant will apply up to 6 patches twice daily for 4 weeks.
Call 214-648-5005
Thomas Schlieve
18 Years and over
Phase 2
This study is NOT accepting healthy volunteers
STU 032018-054
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• OLP patients with at least one visible and measurable symptomatic ulcerative OLP lesion, assessable via OLP Clinician Reported Outcome Measure (OLPClinROM).
• Patients aged ≥ 18 years.
• Patients practicing daily oral hygiene (by tooth brushing and/or mouth rinse) and willing to maintain at least their routine oral hygiene procedure during study participation.
• Willingness to keep already used permitted concomitant medication, food supplements (e.g. probiotics) or herbals, which might have in the discretion of the investigator a potential influence on OLP, on a stable basis during the study.
Exclusion Criteria:

• Patients requiring more than 6 patches (corresponding to an area of approximately 3 cm2 per patch) to cover symptomatic ulcerative and erythematous OLP lesions at baseline visit.
• Ongoing active visible fungal, bacterial or viral infection of oral mucosa, including ongoing treatment of those at baseline.
• Patient with any un-healed oral surgery (including recent diagnostic biopsies, if applicable) or oral laser therapeutic wound(s) at baseline visit.
• Any of the following systemic treatments prior to baseline visit: Corticosteroids, Antibiotics, Retinoids, Immunosuppressive drugs (e.g. azathioprine, cyclosporine, mycophenolate mofetil, or biologics), Antimycotics.
• Any of the following topical treatments used in the oral cavity prior to baseline visit: Corticosteroids, Antibiotics, Cyclosporine, Tacrolimus, Pimecrolimus, Antimycotics, Retinoids.
• Phototherapy in oral cavity prior to baseline visit: UVB, PUVA.
• Current participation in another clinical study and/or having received treatment with any non-marketed / investigational medicinal product (drug substance or medical device) within 4 weeks prior to screening.
• Known or suspected intolerance/hypersensitivity/resistance to clobetasol propionate or any component of the investigational medicinal product.
• Patients who previously have failed to respond to OLP treatments with systemic glucocorticosteroids, methotrexate, cyclosporine, retinoids and/or azathioprine.
• Any history of squamous cell carcinoma (even if resected), as well as history of other non-squamous cell carcinoma (e.g. sarcoma, salivary gland tumors) that have been managed with radiation or chemotherapy.
• History of cancer (except resected cutaneous basal cell carcinoma and except in situ cervical cancer) unless it can be documented that the patient has been in a disease-free state for at least 5 years. In case of clinical suspicion of malignancy in the oral cavity, a patient can only be included after an excluding biopsy.
• Professional dental cleaning within 2 weeks prior to baseline and unwillingness to refrain from professional dental cleaning during study conduct.
• Close affiliation with the investigator (e.g. a close relative) or persons working at the study sites or patient who is an employee of the Sponsor's company.
• Pregnant, confirmed by a positive pregnancy test, or nursing (lactating) women, or women of childbearing potential (WOCP) planning to become pregnant or WOCP not using or willing to continue to use a defined highly effective method of contraception throughout the study.
Drug: Clobetasol Propionate
Oral Lichen Planus
Patch, Rivelin-Clo Patch, Oral Lichen Planus, Ulcerative, Erythematous, OLP, OLPClinROM, OLPSSM
  Email this study information to me
  Contact the study team
  See more information